Cargando…

Diagnostic performance and impact on patient management of [(68)Ga]Ga-DOTA-TOC PET/CT in colorectal neuroendocrine tumors derived from hindgut

The main purpose of this retrospective study was to determine the diagnostic performance of [(68)Ga]Ga-DOTA-D-Phe1-Try3-octreotide(DOTA-TOC) positron emission tomography/computed tomography (PET/CT) in patients with well-differentiated colorectal Neuroendocrine Tumours (NETs) originating from the hi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delabie, Pierre, Baudin, Éric, Hentic, Olivia, Afchain, Pauline, Rusu, Timofei, Montravers, Françoise
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704918/ https://www.ncbi.nlm.nih.gov/pubmed/36451394 http://dx.doi.org/10.1097/MD.0000000000031512

Ejemplares similares

[(68)Ga]Ga-DOTA-TOC: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging
por: Hennrich, Ute, et al.
Publicado: (2020)

Impact of segmentation and discretization on radiomic features in (68)Ga-DOTA-TOC PET/CT images of neuroendocrine tumor
por: Liberini, Virginia, et al.
Publicado: (2021)

Occupational radiation exposure assessment during the management of [(68)Ga]Ga-DOTA-TOC
por: Riveira-Martin, Mercedes, et al.
Publicado: (2022)

Monte Carlo investigation of PET [(68)Ga]Ga-DOTA-TOC activity-administration protocols for consistent image quality
por: Kalaitzidis, Philip, et al.
Publicado: (2023)

Correlations between [(68)Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [(177)Lu]Lu-DOTA-TATE
por: Bruvoll, Ragnar, et al.
Publicado: (2023)

Same-day comparative protocol PET/CT-PET/MRI [(68) Ga]Ga-DOTA-TOC in paragangliomas and pheochromocytomas: an approach to personalized medicine
por: Prado-Wohlwend, Stefan, et al.
Publicado: (2023)

Tumour-to-liver ratio determined by [(68)Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours
por: Kim, Yong-il, et al.
Publicado: (2020)

Highly variable biodistribution of (68)Ga labeled somatostatin analogues (68)Ga-DOTA-NOC and (68)Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT
por: Cheng, Monica, et al.
Publicado: (2022)

Hypoglycemia-Triggered Motion Artifact on (68)Ga-DOTA-TOC Positron Emission Tomography/Computed Tomography
por: Chandra, Piyush, et al.
Publicado: (2021)

Fully automated radiolabeling of [(68)Ga]Ga-EMP100 targeting c-MET for PET-CT clinical imaging
por: Rusu, Timofei, et al.
Publicado: (2023)

Application of (68)Ga-DOTA-TATE PET/CT in metastatic neuroendocrine tumor of gastrointestinal origin
por: Papadakis, Georgios Z., et al.
Publicado: (2017)

PET-CT imaging of pulmonary inflammation using [(68)Ga]Ga-DOTA-TATE
por: Puuvuori, Emmi, et al.
Publicado: (2022)

Comparison of [(18)F]DOPA and [(68)Ga]DOTA-TOC as a PET imaging tracer before peptide receptor radionuclide therapy
por: Veenstra, Emile B., et al.
Publicado: (2022)

Standardized image quality for (68)Ga-DOTA-TATE PET/CT
por: Cox, Christina P. W., et al.
Publicado: (2020)

The value of [68Ga]Ga-DOTA-TATE PET/CT in diagnosis and management of suspected pituitary tumors
por: Novruzov, Fuad, et al.
Publicado: (2021)

Potential value of pre- and post-therapy [68Ga]Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors
por: Opalińska, Marta, et al.
Publicado: (2022)

Diagnostic challenges in a patient with an occult insulinoma:(68 )Ga‐DOTA‐exendin‐4 PET/CT and (68)Ga‐DOTATATE PET/CT
por: Bongetti, Elisa, et al.
Publicado: (2018)

Head-to-Head Comparison of (68)Ga-DOTA-TATE and (68)Ga-DOTA-JR11 PET/CT in Patients With Tumor-Induced Osteomalacia: A Prospective Study
por: Hou, Guozhu, et al.
Publicado: (2022)

Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle
por: Nilica, Bernhard, et al.
Publicado: (2016)

Assessment of regional pulmonary blood flow using (68)Ga-DOTA PET
por: Velasco, Carlos, et al.
Publicado: (2017)

Preparation and Evaluation of [(18)F]AlF-NOTA-NOC for PET Imaging of Neuroendocrine Tumors: Comparison to [(68)Ga]Ga-DOTA/NOTA-NOC
por: Dam, Johan Hygum, et al.
Publicado: (2022)

Instant kit preparation of (68)Ga-radiopharmaceuticals via the hybrid chelator DATA: clinical translation of [(68)Ga]Ga-DATA-TOC
por: Sinnes, Jean-Philippe, et al.
Publicado: (2019)

Adventures in radiosynthesis of clinical grade [(68)Ga]Ga-DOTA-Siglec-9
por: Käkelä, Meeri, et al.
Publicado: (2018)

[(68)Ga]Ga-DOTA-TATE uptake due to COVID-19 vaccination
por: Weiler-Sagie, Michal, et al.
Publicado: (2021)

Role of Combined (68)Ga DOTA-Peptides and (18)F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Kaewput, Chalermrat, et al.
Publicado: (2022)

Preparation and Biological Study of (68)Ga-DOTA-alendronate
por: Fakhari, Ashraf, et al.
Publicado: (2016)

Al[(18)F]F-NOTA-Octreotide Is Comparable to [(68)Ga]Ga-DOTA-TATE for PET/CT Imaging of Neuroendocrine Tumours in the Latin-American Population
por: Haeger, Arlette, et al.
Publicado: (2023)

The role of (68)Ga-DOTA derivatives PET-CT in patients with ectopic ACTH syndrome
por: Ceccato, Filippo, et al.
Publicado: (2020)

Prevalence of Brain Incidental Lesions Detected by (68)Ga-DOTA Peptides PET/CT
por: Albano, Domenico, et al.
Publicado: (2022)

Initial Clinical Experience with (68)Ga-DOTA-NOC Prepared Using (68)Ga from Nanoceria-polyacrylonitrile Composite Sorbent-based (68)Ge/(68)Ga Generator and Freeze-dried DOTA-NOC Kits
por: Chandra, Piyush, et al.
Publicado: (2017)

Pancreatic serous cystoadenoma (CSA) showing increased tracer uptake at 68-GaDOTA-peptide Positron Emission Tomography (68Ga-DOTA-peptide PET-CT): a case report
por: Nappo, Gennaro, et al.
Publicado: (2020)

Relationships between uptake of [(68)Ga]Ga-DOTA-TATE and absorbed dose in [(177)Lu]Lu-DOTA-TATE therapy
por: Stenvall, Anna, et al.
Publicado: (2022)

Impact of (68)Ga-DOTATOC PET/CT in comparison to (111)In-Octreotide SPECT/CT in management of neuro-endocrine tumors: A case report
por: Tolomeo, Anna, et al.
Publicado: (2020)

Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
por: Opalinska, Marta, et al.
Publicado: (2023)

(68)Ga-PSMA and (68)Ga-DOTA-RM2 PET/MRI in Recurrent Prostate Cancer: Diagnostic Performance and Association with Clinical and Histopathological Data
por: Mapelli, Paola, et al.
Publicado: (2022)

Scale down and optimized automated production of [68Ga]68Ga-DOTA-ECL1i PET tracer targeting CCR2 expression
por: Migliari, Silvia, et al.
Publicado: (2023)

Physiological Biodistribution of (68)Ga-DOTA-TATE in Normal Subjects
por: Özgüven, Salih, et al.
Publicado: (2021)

Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F]FDG PET/MRI in the Preoperative Diagnosis of Gastric Cancer
por: Du, Tao, et al.
Publicado: (2023)

The Impact of Total Variation Regularized Expectation Maximization Reconstruction on (68)Ga-DOTA-TATE PET/CT Images in Patients With Neuroendocrine Tumor
por: Liu, Lin, et al.
Publicado: (2022)

(68)Ga-DOTA-NT-20.3 Neurotensin Receptor 1 PET Imaging as a Surrogate for Neuroendocrine Differentiation of Prostate Cancer
por: Wu, Wenyu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o1ctaitc5i84kk389icmvj1s10